MEDI-524 (Motavizumab) for the Prevention of Respiratory Sycytial Virus (RSV) Disease Among Native American Indian Infants in the Southwestern United States

NCT00121108 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2127

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

BIOLOGICAL: Motavizumab
OTHER: Placebo

Sponsor

MedImmune LLC